Skye Bioscience, Inc.
$0.78
▲
4.98%
2026-04-21 09:26:01
skyebioscience.com
NGM: SKYE
Explore Skye Bioscience, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$26.15 M
Current Price
$0.78
52W High / Low
$5.75 / $0.57
Stock P/E
—
Book Value
$0.6
Dividend Yield
—
ROCE
-289.25%
ROE
-1.27%
Face Value
—
EPS
$-1.41
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
12
Beta
2.87
Debt / Equity
1.37
Current Ratio
3.3
Quick Ratio
3.3
Forward P/E
-0.67
Price / Sales
—
Enterprise Value
$-1.43 M
EV / EBITDA
0.03
EV / Revenue
—
Rating
Buy
Target Price
$8.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Insmed Incorporated | $143.43 | — | $31.02 B | — | -55.4% | -2.49% | $212.75 / $63.81 | $3.45 |
| 2. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 3. | Jazz Pharmaceuticals plc | $200.82 | — | $12.38 B | — | 5.5% | -8.47% | $207.48 / $97.5 | $70.3 |
| 4. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 5. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 6. | Incyte Corporation | $97.69 | 15.26 | $19.46 B | — | 24.67% | 29.87% | $112.29 / $56.13 | $26.04 |
| 7. | SAB Biotherapeutics, Inc. | $3.86 | 14.78 | $196.16 M | — | -30.19% | 14.96% | $6.6 / $1.3 | $3.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -14.9 M | -13.26 M | -18.24 M | -11.76 M | -12.35 M | — |
| Net Profit | -14.44 M | -12.75 M | -17.62 M | -11.1 M | -9.75 M | — |
| EPS in Rs | -0.43 | -0.38 | -0.53 | -0.33 | -0.29 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -58.16 M | -36.43 M | -13.67 M | -12.11 M |
| Net Profit | -55.92 M | -26.57 M | -37.64 M | -19.48 M |
| EPS in Rs | -1.68 | -0.8 | -1.13 | -0.58 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 28.31 M | 72.76 M | 11.94 M | 9.11 M |
| Total Liabilities | 8.29 M | 4.61 M | 14.07 M | 12.12 M |
| Equity | 20.02 M | 68.15 M | -2.13 M | -3.01 M |
| Current Assets | 27.09 M | 70.83 M | 11.65 M | 8.94 M |
| Current Liabilities | 8.21 M | 4.34 M | 13.9 M | 12.12 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -43.06 M | -25.24 M | -13.95 M | -12.74 M |
| Investing CF | -19.5 M | -0.25 M | 6.6 M | 5.21 M |
| Financing CF | 0.03 M | 83.56 M | 16.44 M | -0.21 M |
| Free CF | -43.07 M | -26.84 M | -13.96 M | -12.77 M |
| Capex | -0.01 M | -1.6 M | -0.01 M | -0.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 29.43% | -93.23% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-09-08 | 1:0.004 |